

Employing the European Thyroid Imaging Reporting and Data System 2017 classification in a malignancy risk stratification system for thyroid nodules at Can Tho Oncology Hospital from 2021 to 2023

Vo Van Kha,¹ Tran Thi Huong Ly,^{2,3} Pham Thi Thanh Hoa,^{4,5} Vo Huynh Nhu⁶

¹Director Board, Can Tho Oncology Hospital; ²Department of Pathophysiology – Immunity, Can Tho University of Medicine and Pharmacy; ³Department of General Planning, Can Tho Oncology Hospital; ⁴Department of Internal Medicine, Can Tho Oncology Hospital; ⁵Department of Nutrition and Food Safety, Ha Noi Medical University; ⁶Can Tho University of Medicine and Pharmacy, Vietnam

Correspondence: Tran Thi Huong Ly, Department of Pathophysiology – Immunity, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.
E-mail: bshuongly@gmail.com

Key words: risk stratification systems, EU-TIRADS 2017, ACR-TIRADS 2017, thyroid nodules.

Contributions: VVK, conceptualization; TTHL, data curation and formal analysis; VHN, methodology; PTTH, writing – original draft.

Conflict of interest: the authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics approval and consent to participate: the institutional review board of Can Tho Oncology Hospital approved this prospective study (Ref: 789/QĐ-BVUB). Informed consent of authorized guardians of patients was obtained.

Informed consent: before study participation, written informed consent was obtained from the patient.

Patient consent for publication: all patients provided written informed consent for publication of their data.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Funding: none.

Received: 5 November 2024.

Accepted: 14 November 2024.

Early view: 29 April 2025.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Italian Journal of Medicine 2025; 19:1852

doi:10.4081/ijm.2025.1852

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

ABSTRACT

Thyroid nodules are extremely common, accounting for up to 68% of all random ultrasound examinations in adults. They are mostly benign. Early detection of nodules and risk stratification systems (RSS) are critical for guiding monitoring and treatment. The primary methods for managing thyroid nodules are ultrasound and fine-needle aspiration biopsy. Thyroid Imaging Reporting and Data Systems (TIRADS) have been developed worldwide, utilizing ultrasound features such as composition, margin, shape, and echogenicity. Many countries have conducted research on the EU-TIRADS classification system, which focuses on key malignant features while remaining easily accessible. The objectives of this study are to describe imaging characteristics and assess thyroid nodules using the European (EU)-TIRADS 2017 ultrasound system and to compare results to histopathological outcomes and the American College of Radiology (ACR)-TIRADS 2017 systems. The study included patients who had ultrasound findings described using the TIRADS system, underwent surgery, and had histopathological results available. The study used a cross-sectional descriptive methodology. In examining 435 thyroid nodules in 347 patients, a male-to-female ratio of 1:5, an average age of 44 years, and an average size of 25 mm were found. Comparing EU-TIRADS to histopathology and ACR-TIRADS, the system's malignancy risk increased progressively from R2 to R5: 0%, 9.2%, 62.8%, and 93.0%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for distinguishing between benign and malignant nodules were 91.2%, 81%, 81.6%, 91.3%, and 86.2%. The EU-TIRADS 2017 system proved to be extremely useful in assessing thyroid nodules, particularly in the TIRADS 5 classification.

Introduction

In the general population, nodular lesions in the thyroid gland are very common, with a frequency of up to 68% when performing incidental ultrasound in adults with high-resolution probes.¹ The majority of lesions are benign. Since more than 90% of thyroid cancers are well-differentiated, progress silently, have a low level of malignancy with a good prognosis, and have a 5-year survival rate of 95-97%,^{2,3} detecting

early-stage thyroid nodules and malignant risk stratification (RSS) will help guide disease monitoring and treatment. Currently, the two main methods used to manage and monitor simple thyroid nodules are ultrasound and fine needle aspiration cytology, which can be repeated with cytology or surgical histopathological diagnosis in cases of intermediate-risk thyroid nodules.⁴ In the world, there are many Thyroid Imaging Reporting and Data Systems (TIRADS) to classify thyroid nodules based on ultrasound characteristics of borders, shape, echogenicity, and echogenicity components, especially European (EU)-TIRADS 2017 and American College of Radiology (ACR)-TIRADS 2017. Updates recommend fine-needle aspiration, depending on the size of the thyroid nodule.⁵ In particular, the EU-TIRADS classification table evaluates mainly the main malignant features but does not reduce their value, and it has been researched and applied in many countries, and Vietnam. Therefore, to contribute to the assessment of the value of EU-TIRADS and to continue the research on ACR-TIRADS classification at Can Tho City Oncology Hospital, we performed an analysis with the goal of i) describing the imaging characteristics and evaluate thyroid nodular lesions on ultrasound according to the EU-TIRADS 2017 classification and ii) surveying the value of the EU-TIRADS 2017 system through comparison with histopathological results and ACR-TIRADS.

Materials and Methods

Subjects

The study evaluated 347 patients with 435 cases of thyroid nodules and was conducted at Can Tho Oncology Hospital between June 2021 and April 2023. Patients were selected for the sample when they had an ultrasound assessment of characteristics according to the TIRADS system, were indicated for surgical removal of thyroid nodule lesions, and had histopathology results. The patients had surgery because of suspected malignant thyroid nodules or large-sized damage affecting the quality of life.

Methods

This is a prospective, cross-sectional study with a convenient sample size. The sample size was calculated with Eq. 1:

$$TP+FN = \frac{Z_{\alpha}^2 \times p_{sp} \times (1-p_{sp})}{c^2} \quad [\text{Eq. 1}]$$

$$n_{(sp)} = \frac{FP+TN}{p_{dis}}$$

Where: Z_{α} is the desired confidence level of 95% ($Z_{\alpha} = 1.96$); p_{sp} is the probability of specificity (84.3%) according to research by Castellana *et al.*;⁶ C is the allowable error (6%); and p_{dis} is the prevalence of thyroid nodules (68%).⁷

Substituting into the formula, we get the minimum sample size needed for the study, which is 207.

This study was approved by the institutional review board of Can Tho Oncology Hospital (Ref: 789/QĐ-BVUB). All patients gave informed consent to participate in the study, and their personal information was kept confidential.

A Siemens Acuson Juniper ultrasound machine with a linear probe frequency of 6.7-10 MHz was used for patients admitted to the hospital for thyroid nodule surgery. According to the EU TIRADS classification on ultrasound, TIRADS 2,3 lesions were classified as benign, and TIRADS 4,5 lesions were classified as malignant. Record postoperative surgical reports and collect histopathological results; classify diseased tissue into benign and malignant groups according to the World Health Organization 2017 data processing is performed using SPSS 20.0 software. The EU-TIRADS 2017 system is presented in a summary diagram (Figure 1).⁸

Results

General characteristics of research subjects

This study included 347 patients with 435 thyroid nodules. Among them, 262 patients had one nodule, and 85 patients had two or more nodules. The incidence of the disease in women is higher than in men, with a male/female ratio of 1/5. The average age when thyroid damage was detected was 44.5 ± 12.196 years, with the youngest being 13 and the oldest being 79. The average size of thyroid nodules is 25.4 ± 16.62 mm, with the smallest size being 3mm and the largest being 100 mm (Table 1).

Table 1. Epidemiological characteristics of thyroid nodules.

General features	Histopathological results		Total	p
	Benign	Malignant		
Armor multiplier number, n (%)	231 (53.1)	204 (46.9)	435 (100)	
Sex, n (%)				
Male	17 (29.8)	40 (70.2)	57	<0.05
Female	136 (46.9)	154 (53.1)	290	
Average age	44.7±11	44.4±13.6	44±12.9	>0.05
Living area, n (%)				
City	47 (46.1)	55 (53.9)	102	>0.05
Countryside	106 (43.2)	139 (56.7)	245	
Location				
Right lobe	112	112	224	>0.05
Left lobe	113	86	199	
Isthymus	6	6	12	
Middle size	31.64±16.06	18.33±14.3	25.4±16.6	<0.05

Men have a higher risk of malignant thyroid nodule lesions than women ($p < 0.05$). The average size between the two groups of lesions is also statistically significant; the average size of malignant lesions is 18.33 ± 14.3 mm, while benign lesions are 31.64 ± 16.06 mm. However, there were no statistically significant differences in average age, living area, and location of the lesion.

Ultrasound imaging characteristics of thyroid nodules with histopathological results

The highest proportion was recorded of lesions with both solid and cystic components, hypoechoic, well-defined, oval shape, and no internal echogenic nodules (Table 2).

High suspicion features of EU-TIRADS 5 all show high specificity (including markedly hypoechoic, irregular margins encroaching beyond the thyroid gland, and taller-

than-wide microcalcifications), while the sensitivity is not high. The reverb is poor, and the sensitivity is quite good (Figure 2).

Value of the European Thyroid Imaging Reporting and Data System 2017

Comparing the results of the EU-TIRADS system with histopathology, the corresponding malignancy rates of each EU-TIRADS group 2, 3, 4, and 5 are 0%, respectively; 9.2%, 62.8%, and 93% are consistent with world studies (Figure 3).

Analyzing the receiver-operating characteristic (ROC) curve, the area under the curve (AUC) of EU is 0.91, and the ACR is 0.90 (≥ 0.9). To achieve an optimal balance between sensitivity and specificity, we choose R4 (EU) and TR4 (ACR) as the cut-off points (Figure 4).




Figure 1. European Thyroid Imaging Reporting and Data System 2017 classification scheme.⁸ Fine needle aspiration should be performed in case suspicious lymph nodes are found. FNA, fine needle aspiration; EU-TIRADS, European Thyroid Imaging Reporting and Data System.




Figure 2. Sensitivity (SEN) and specificity (SPE) chart of some ultrasound characteristics suggestive of malignancy.

Table 2. Ultrasound imaging characteristics of thyroid nodules according to the Thyroid Imaging Reporting and Data System.

Ultrasound image characteristics	Histopathological results, n (%)		Total	p
	Malignant	Benign		
Composition				<0.001
Cystic	0	6 (100)	6	
Spongiform	0	5 (100)	5	
Mixed cystic and solid	55 (25.1)	164 (74.9)	219	
Solid or almost completely solid	149 (72.7)	56 (27.3)	205	
Echogenicity				<0.001
Anechoic	0	6 (100)	6	
Spongiform	0	5 (100)	5	
Hyperechoic or isoechoic	34 (15.9)	180 (84.1)	214	
Hypoechoic	147 (79.9)	37 (20.1)	184	
Markedly hypoechoic	23 (88.5)	3 (11.5)	26	
Margins				<0.001
Well-defined	117 (35.3)	214 (64.7)	331	
Irregular margins (spiculated/microlobulated)	60 (96.8)	2 (3.2)	62	
Ill-defined margin	14 (48.3)	15 (51.7)	29	
Extrathyroidal extension	13 (100)	0	13	
Shape				<0.001
Wider-than-tall (oval)	168 (42.4)	228 (57.6)	396	
Round	7 (87.5)	1 (12.5)	8	
Taller-than-wide	29 (93.5)	2 (6.5)	31	
Components inside the lesion				<0.001
None	118 (40.7)	172 (59.3)	290	
Comet tail	2 (18.2)	9 (81.8)	11	
Macrocalcification	28 (40)	42 (60)	70	
Peripheral calcification	8 (61.5)	5 (38.5)	13	
Microcalcification	48 (94.1)	3 (5.9)	51	
Total	204	231	435	Fisher's exact test

Comparing the EU-TIRADS and ACR-TIRADS systems, we see that ACR-TIRADS has high specificity and positive predictive value, while EU-TIRADS has sensitivity and a higher negative predictive value (Table 3).

Discussion

General characteristics of research subjects

Our study was performed on 347 patients. There was a clear difference in the proportion of patients with thyroid nodular lesions. According to gender, with a male/female ratio of 1/5, men have a higher risk of malignant thyroid nodules than women. In terms of size, the benign lesion group often has a larger average size than the malignant lesion group. Consistent with the research of author Fan Xiao *et al.*, they studied a group of 434 pathologically confirmed thyroid nodules, including 259 malignant thyroid nodules: male/female ratio is 1/5; 61.4% of men had malignant lesions; the average age was 45±12 years old. The average size of benign lesions is 20±14 mm, and malignant lesions are 11.5±8 mm.⁹

Ultrasound imaging characteristics of thyroid nodular lesions compared with histopathological results

Compositions

100% of cysts and sponges are benign; mixed components account for 74.9% of benign lesions. Besides, the predominant solid component is malignant, with a rate of 72.7%, consistent with the systematic analysis of Molina-Vega *et al.*, with 82-91% of malignant lesions being solid components.¹⁰

Echogenicity

Hypoechoic thyroid nodules have the highest rate and are predominantly malignant, while markedly hypoechoic thyroid nodules suggest high malignancy with a rate of 88.5%, similar to the study by Kovatcheva *et al.* in 942 thyroid nodules.¹¹

Shape

Most lesions have an oval shape, and non-oval lesions often show histopathological results as malignant lesions. In 2018, Xu *et al.* studied 2465 thyroid nodules and showed that

Table 3. The value of the European Thyroid Imaging Reporting and Data System grading in diagnosing thyroid cancer.

TIRADS classification	Malignant	Benign	SEN (%)	SPE (%)	PPV (%)	NPV (%)	ACC (%)
EU 4-5	186	42	91.2	81	81.6	91.3	86.2
EU 2-3	18	189					
ACR 4-5	177	39	86.8	83.1	81.9	87.7	84.8
ACR 1-3	27	192					

EU, European; ACR, American College of Radiology; SEN, sensitivity; SPE, specificity; PPV, positive predictive value; NPV, negative predictive value; ACC, accuracy.




Figure 3. The p-charts stratify thyroid nodule lesions according to the European (EU) Thyroid Imaging Reporting and Data System (TIRADS) and the American College of Radiology (ACR) TIRADS.




Figure 4. Receiver-operating characteristic (ROC) curve graph of two Thyroid Imaging Reporting and Data Systems. EU, European; ACR, American College of Radiology.

81.5% of the taller-than-wide nodules are malignant.¹² A growth pattern demonstrating a “taller-than-wide” appearance (defined as an anteroposterior diameter that exceeds the transverse diameter) when imaging the thyroid in the transverse plane is predictive of malignancy.

Margins

Most lesions were well-defined, accounting for 75.2%, with 64.7% of them being benign. Groups of lesions suggestive of malignancy had irregular margins (including spiculated, lobulated, or multi-arcillary) and invasion beyond the thyroid gland, with malignant rates of 96.8% and 100%, respectively, consistent with research by Skowrońska *et al.*, with irregular margins accounting for a high rate of malignancy (75%) in 140 thyroid nodules.¹³ Shen *et al.* had 2.6% of nodules that invaded outside the thyroid gland that were malignant.¹⁴

Internal components

The majority of lesions have no internal echogenic nodules at a rate of 66.7%; 81.8% of lesions with comet tail artifacts are benign; coarse calcification lesions are usually benign. The malignant rate of lesions with microcalcifications and rim calcifications is quite high, at 94.1% and 61.5%, respectively. Similar to the study by Kovatcheva *et al.*, 75% of lesions have no echogenic nodules inside, and the rate of malignancy in lesions with thick echo spots is 63.1%.¹¹

Value of the European Thyroid Imaging Reporting and Data System 2017

Comparing the results of EU-TIRADS classification with histopathology, the proportion of lesions distributed according to EU-TIRADS groups 2, 3, 4, and 5 is 2.5%, respectively; 45.1%; 19.8%; and 32.6%, with the corresponding malignancy rate of each group being 0%, respectively; 9.2%, 62.8%, and 93.0%. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in distinguishing benign and malignant lesions were 91.2%, 81%, and 81.6%, respectively, 91.3% and 86.2%. In the study by Hekimsoy *et al.*, with 251 thyroid nodules, including 189 benign nodules (75.30%) and 62 malignant nodules (24.70%), based on histological assessment, sensitivity, and specificity rates were 73% and 80% for EU-TIRADS, with an AUC of 0.8.¹⁵ A systematic analysis by Castellana *et al.* with databases searched and retrieved up to December 2019, including 7 studies, evaluated 5672 thyroid nodules. The incidence of malignancy in each group according to EU-TIRADS was R2=0.5%, TR3=5.9%, R4=21.4%, and R5=76.1%. The sensitivity, specificity, positive predictive value, and negative predictive value of R5 are 83.5%, 84.3%, 76.1%, and 85.4%, respectively.⁶

Conclusions

After studying 435 thyroid nodules in 347 patients, it was found that female patients predominated, and men had a higher risk of malignancy. The average size of malignant lesions is usually smaller than that of benign lesions. According to the 2017 EU-TIRADS system, signs suggestive of malignancy include a taller-than-wide, irregular margins, invasion

beyond the thyroid gland, thick echo spots, and markedly hypoechoic, indicating a high risk of cancer.

When comparing EU-TIRADS system results with histopathology, group R5 had the highest malignancy rate. The ROC AUC of EU-TIRADS >0.9 showed a very good ability to discriminate between benign and malignant thyroid nodule lesions, with high sensitivity and negative predictive value.

References

1. Noto B, Eveslage M, Pixberg M, et al. Prevalence of hyperfunctioning thyroid nodules among those in need of fine needle aspiration cytology according to ATA 2015, EU-TIRADS, and ACR-TIRADS. *Eur J Nucl Med* 2020;47:1518-26.
2. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *JAMA* 2013;309:1493-501.
3. Ross DS. Nonpalpable thyroid nodules—managing an epidemic. *J Clin Endocrinol Metab* 2002;87:1938-40.
4. Trimboli P, Durante C. Ultrasound risk stratification systems for thyroid nodule: between lights and shadows, we are moving towards a new era. *Endocrine* 2020;69:1-4.
5. Hoang JK, Middleton WD, Farjat AE, et al. Reduction in thyroid nodule biopsies and improved accuracy with American College of Radiology Thyroid Imaging Reporting and Data System. *Radiology* 2018;287:185-93.
6. Castellana M, Grani G, Radzina M, et al. Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: a meta-analysis. *Eur J Endocrinol* 2020;183:255-64.
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26:1-133.
8. Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. *Eur Thyroid J* 2017;6:225-37.
9. Xiao F, Li J, Han Z, et al. Multimodality US versus thyroid imaging reporting and data system criteria in recommending fine-needle aspiration of thyroid nodules. *Radiology* 2023;307:1-10.
10. Molina-Vega M, Rodríguez-Pérez CA, Álvarez-Mancha AI, et al. Clinical and ultrasound thyroid nodule characteristics and their association with cytological and histopathological outcomes: a retrospective multicenter study in high-resolution thyroid nodule clinics. *J Clin Med* 2019;8:2172.
11. Kovatcheva RD, Shinkov AD, Dimitrova ID, et al. Evaluation of the diagnostic performance of EU-TIRADS in discriminating benign from malignant thyroid nodules: a prospective study in one referral center. *Eur Thyroid J* 2021;9:304-12.
12. Xu T, Wu Y, Wu RX, et al. Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination. *Endocrine* 2019;64:299-307.
13. Skowrońska A, Milczarek-Banach J, Wiechno W, et al.

- Accuracy of the European Thyroid Imaging Reporting and Data System (EU-TIRADS) in the valuation of thyroid nodule malignancy in reference to the post-surgery histological results. *Pol J Radiol* 2018;83: e579-86.
14. Shen Y, Liu M, He J, et al. Comparison of different risk-stratification systems for the diagnosis of benign and malignant thyroid nodules. *Front Oncol* 2019;9:378.
15. Hekimsoy I, Öztürk E, Ertan Y, et al. Diagnostic performance rates of the ACR-TIRADS and EU-TIRADS based on histopathological evidence. *Diagn Interv Radiol* 2021; 27:511-8.